Using compression therapy to prevent nerve damage in breast cancer patients
Official title: Prevention of Chemotherapy-induced Polyneuropathy (CIPN) Using Compressive Therapy
Run by Masaryk Memorial Cancer Institute · NCT06823440 · Data updated 2026-11-12
This study is testing if wearing special compression gloves and knee socks can help breast cancer patients avoid nerve damage caused by chemotherapy.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 70 Years |
| Sex | Women only |
| Enrollment | 100 (estimated) |
| Sponsor | Masaryk Memorial Cancer Institute Academic / other |
| Drugs / interventions | Chemotherapy |
| Locations | 1 site (Brno) |
| Status | Recruiting |
| Started | February 1, 2025 |
| Main results expected | December 31, 2027 |
| Study ends | December 31, 2028 |
| Registry record updated | April 17, 2026 |
| Trial ID | NCT06823440 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are breast cancer patients aged 18-70 who are receiving (neo)adjuvant treatment with paclitaxel and have an ECOG performance status of 0-2.
✕Probably not a fit
Patients with metastatic disease, prior neuropathy, or those who have received certain chemotherapy treatments may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the effectiveness of compressive therapy, specifically using surgical gloves and compression knee socks, to prevent chemotherapy-induced peripheral neuropathy (CIPN) in patients undergoing treatment for breast cancer. CIPN is a common and debilitating side effect of certain chemotherapy drugs, which can significantly affect patients' quality of life. The study will assess the efficacy of this intervention through quality-of-life questionnaires, hand strength and coordination tests, and laboratory analyses to identify predictive markers of neuropathy. The goal is to enhance CIPN prevention and potentially integrate this method into clinical practice.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the incidence of CIPN, improving the quality of life for breast cancer patients undergoing chemotherapy.
How similar studies have gone: Previous research has indicated that compression therapy can effectively reduce CIPN, suggesting that this approach may be promising.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18-70 years at the time of signing the informed consent (IC). * Signed informed consent. * Breast cancer stages I-III * ECOG performance status 0-2. * (Neo)adjuvant treatment with paclitaxel weekly. Exclusion Criteria: * Metastatic disease. * History of neuropathy/vasculopathy and its pharmacological treatment. * Type I or II diabetes. * Stroke within the last 6 months. * Prior treatment with taxanes and/or cisplatin derivatives. * Peripheral arterial ischemia.
Where it's running
-
Masaryk Memorial Cancer Institute
Brno, Czechia Recruiting
Study contacts
- Principal investigator: Tatiana Ciprova, MBA — Masaryk Memorial Cancer Institute
- Study coordinator: Martina Lojova, Ph.D.
- Email: martina.lojova@mou.cz
- Phone: +420543136232
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Cryotherapy during weekly paclitaxel to reduce chemotherapy-induced numbness and tingling
This study tests whether applying cryotherapy to hands and feet during weekly paclitaxel helps prevent CIPN in women with breast cancer.
-
AMH and Hormonal Profiles in Women with Breast Cancer
This study tests AMH and other hormonal markers in women with breast cancer and in healthy controls to see how these levels look in real-world care and whether AMH testing can fit into routine practice.
-
ctDNA blood test to spot buried cancer after surgery or treatment in colorectal cancer
A blood test that looks for specific KRAS mutations in circulating tumor DNA to see if colorectal cancer has left residual disease or is likely to relapse.
-
Detecting BRAF V600E in Blood with a CRISPR/Cas12a Lab Test
This study tests a blood-based test that uses CRISPR/Cas12a to detect the BRAF V600E mutation in patients with unresectable metastatic melanoma.
-
HPV-positive Oropharyngeal Carcinoma: tracking HPV in saliva, washings and blood during radiotherapy
This study tests a new electrochemical method to monitor HPV DNA in patients with HPV-positive oropharyngeal cancer during treatment, using saliva, oral rinse, and blood.
-
Comprehensive Prehabilitation Program for Locally Advanced Esophagogastric Cancer
This trial tests if a personalized prehabilitation plan with nutrition, exercise, and psychological support helps patients with locally advanced esophageal, GEJ, or gastric cancer before surgery.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.